Tiffany Goolsby, PharmD, BCIDP
banner
tiffanygoolsby.bsky.social
Tiffany Goolsby, PharmD, BCIDP
@tiffanygoolsby.bsky.social
Antimicrobial Stewardship and Infectious Diseases Pharmacist||
Subject Matter Expert for Bitscopic's clinical surveillance software, PraediAlert
Excited to work with the best! Welcome Kelly!
November 11, 2025 at 4:01 PM
Reposted by Tiffany Goolsby, PharmD, BCIDP
Recurrent C. diff = financial drain and preventable patient harm. Protect your 💰 and well-being with PraediAlert which has prevention strategies like real-time alerts, antimicrobial stewardship, hand hygiene tracking. tinyurl.com/3zr75ej4 #CDiff #InfectionControl
Economic impact of multiple recurrent Clostridioides difficile infection in a community teaching hospital | Infection Control & Hospital Epidemiology | Cambridge Core
Economic impact of multiple recurrent Clostridioides difficile infection in a community teaching hospital
tinyurl.com
October 30, 2025 at 12:00 PM
Reposted by Tiffany Goolsby, PharmD, BCIDP
Infection Prevention Week 2025: we want to recognize the incredible work IPs do every day. You are the shield between patients & the threat of infection. You educate teams & tirelessly enforce the standards that keep hospitals & communities safe.

#IIPW #InfectionPrevention #Infection
October 24, 2025 at 12:00 PM
Reposted by Tiffany Goolsby, PharmD, BCIDP
Your next sepsis data analyst might be… an LLM.
A JAMA Network Open study used LLaMA 3 to parse >100k clinical notes, clustering symptoms that predicted infection source, resistance, & mortality—with 99% accuracy.

🔗 jamanetwork.com/journals/jam...

#Sepsis #AI #ClinicalResearch
Syndromic Analysis of Sepsis Cohorts Using Large Language Models
This cohort study compares the performance of a large language model against manual medical record review for extracting presenting signs and symptoms data from hospital admission notes and uses these...
jamanetwork.com
October 27, 2025 at 1:07 PM
October 18, 2025 at 9:16 PM
Reposted by Tiffany Goolsby, PharmD, BCIDP
A “negative” dalbavancin trial doesn’t mean a dead end—it means opportunity. @PaulSaxMD highlights why even when results aren’t what we hoped for, there’s room for optimism in innovation, stewardship, and trial design. Read more: tinyurl.com/3m9wj28k

#AntibioticStewardship #Dalbavancin

DOTS: Optimism Around a “Negative” Dalbavancin Trial
The DOTS randomized clinical trial of dalbavancin versus standard-of-care for Staph aureus bacteremia (SAB) just landed in JAMA, where it undoubtedly will be featured in numerous ID, hospitalist, and medical resident journal clubs over the next several months. Proof:  one of our great second-year ID fellows tagged it immediately for his journal club literally the […]
tinyurl.com
October 14, 2025 at 12:00 PM
Reposted by Tiffany Goolsby, PharmD, BCIDP
New data show shifts in carbapenemase-producing CRE from 2019–2023. KPC remains most common, but NDM and other metallo-β-lactamases are rising. doi.org/10.7326/ANNA...
PraediAlert can help monitor resistance patterns in your facility. #AMR #PraediAlert
October 1, 2025 at 12:00 PM
Reposted by Tiffany Goolsby, PharmD, BCIDP
The FDA has officially rescinded its 2024 rule on laboratory developed tests (LDTs) confirming that oversight belongs under CLIA.

What does this mean for clinical labs? bitscopic.com/the-fda-back...
The FDA Backpedals on LDTs: What It Means for Clinical Labs
Understand the FDA's role in laboratory developed tests as oversight transitions back to CLIA for better lab regulation clarity.
bitscopic.com
October 1, 2025 at 5:37 PM
Reposted by Tiffany Goolsby, PharmD, BCIDP
Summer's over, but the fight against HAIs continues! These are the top 5 topics from the season:

+ Borescopes in Sterile Processing
+ Risks of unauthorized UVC devices
+ Emerging pathogens (BOTM)
+ Dental assistant training & more

Stay ahead of the curve:
Top 5 Infection Prevention Articles of Summer 2025
Check out the top 5 infection control and prevention articles for Summer 2025! Perennial articles like Bug of the Month and The Clean Bite, and a look at borescopes in sterile processing.
www.infectioncontroltoday.com
October 2, 2025 at 12:00 PM
Reposted by Tiffany Goolsby, PharmD, BCIDP
🩺 Can reducing the frequency of monitoring safely lessen the burden on OPAT teams and patients?

In 420 patients, only 2% had lab abnormalities linked to readmission or treatment change.

academic.oup.com/ofid/article...

#OPAT #AntimicrobialStewardship #IDPharmacy
Evaluation of the safety of cefazolin monotherapy in outpatient parenteral antimicrobial therapy at a large academic medical center
Abstract. In outpatient parenteral antimicrobial therapy, weekly lab monitoring is often standard practice, even for antimicrobials with low complication r
academic.oup.com
October 6, 2025 at 12:59 PM
Reposted by Tiffany Goolsby, PharmD, BCIDP
🔑 HI-PRO Trial (NEJM): In pts w/ provoked VTE + enduring risk factors, 12 mo of low-dose apixaban ↓ recurrent VTE (1.3% vs 10%) vs placebo, w/ low major bleed risk. www.nejm.org/doi/full/10.... #VTE #Thrombosis #NEJM
Apixaban for Extended Treatment of Provoked Venous Thromboembolism | NEJM
The appropriate duration of anticoagulation for venous thromboembolism (VTE) in patients who have a transient provoking factor (e.g., surgery, trauma, or immobility) and concomitant enduring risk f...
www.nejm.org
September 29, 2025 at 12:43 PM
Reposted by Tiffany Goolsby, PharmD, BCIDP
Research shows that educating and empowering patients can improve central line care practices. This highlights how a multi-pronged approach, from data-driven alerts to patient partnership, is crucial for preventing infections. #PraediAlert #PatientCare #DataDrivenHealthcare
Impact of empowerment of onco-hematological patients on the incidence of catheter-related bloodstream infections
Patients with hematologic malignancies and hematopoietic stem cell transplant recipients (HSCT) are at high risk of central venous catheter-related bloodstream infections (CLABSI). Global actions have encouraged patient empowerment as a strategy to reduce these infections. We aim to evaluate the impact of patient empowerment in reducing the incidence density (ID) of CLABSI.
www.ajicjournal.org
September 25, 2025 at 12:00 PM
Reposted by Tiffany Goolsby, PharmD, BCIDP
🦠💊 How long should we treat bacteremia?

Ep. 121 of Breakpoints podcast dives into the BALANCE trial, exploring 7 vs 14 days of antibiotics in critically ill pts.

What does this mean for stewardship? Tune in: breakpoints-sidp.org...

#SIDP #ASP
#121 - Finding BALANCE In Antibiotic Durations: The BALANCE Trial – Breakpoints: The SIDP Podcast
In this second-ever collaboration between SIDP’s Breakpoints and ESCMID’s Communicable podcasts, hosts Erin McCreary and Angela Huttner invite the two
breakpoints-sidp.org
September 22, 2025 at 12:00 PM
Does your institution reflex to urine cultures?
September 15, 2025 at 3:14 PM
Reposted by Tiffany Goolsby, PharmD, BCIDP
Should we extend the use of oral antibiotics in infective endocarditis? The ENDO-ORAL study url: academic.oup.com/cid/article/...
Should we extend the use of oral antibiotics in infective endocarditis? The ENDO-ORAL study
This real-life study showed that switching from intravenous to oral antibiotic therapy in infective endocarditis was effective and safe, including in patie
academic.oup.com
August 25, 2025 at 12:39 PM
Reposted by Tiffany Goolsby, PharmD, BCIDP
Stay ahead of trends! The latest CDC data highlights ongoing surveillance for viruses and bacteria beyond flu, COVID-19, and RSV, like Mycoplasma pneumonia and pertussis.

Use PraediAlert to quickly identify and respond to changing illness patterns in your facility.
Other Respiratory Illnesses Going Around
This page details respiratory illnesses from viruses and bacteria other than COVID-19, flu, and RSV
www.cdc.gov
August 14, 2025 at 12:00 PM
Reposted by Tiffany Goolsby, PharmD, BCIDP
Finally published
🆕🔥DOTS RCT
Among participants with complicated S aureus bacteremia who achieved blood culture clearance, dalbavancin was not superior to standard therapy for achieving a more desirable outcome at day 70 #idsky
jamanetwork.com/journals/jam...
August 13, 2025 at 3:07 PM
Reposted by Tiffany Goolsby, PharmD, BCIDP
Long-acting lipoglycopeptides can provide a convenient alternative to daily antibiotic infusions for enterococcal endocarditis.

doi.org/10.1093/ofid...

PraediAlert can help you monitor OPAT patients to ensure proper follow up care.

#PraediAlert #OPAT #endocarditis
August 13, 2025 at 12:00 PM
Reposted by Tiffany Goolsby, PharmD, BCIDP
*New* 2025 Clinical Practice Guideline Update by the IDSA on the Treatment and Management of COVID-19: Pemivibart for Pre-exposure Prophylaxis, Vilobelimab for Critical Illness, and Abatacept or Infliximab for Severe or Critical Illness

academic.oup.com/cid/article/...

#IDsky #pharmsky
2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Pemivibart for Pre-exposure Prophylaxis, Vilobelimab for Critical Ill...
Abstract. As the first part of several focused updates to the clinical practice guideline on the treatment and management of COVID-19 in adults, children,
academic.oup.com
August 11, 2025 at 12:15 PM
Reposted by Tiffany Goolsby, PharmD, BCIDP
While some recent studies have raised the concern that DoxyPEP leads to increased tetracycline resistance in multiple organisms, this study demonstrates a decrease in overall antibiotic use for treating STIs.

doi.org/10.1093/jac/... #PharmSky

#IDSky
July 30, 2025 at 12:00 PM
They are finally here!
The Complicated UTI Guidelines from IDSA are officially published.

www.idsociety.org/pr...

#IDSky
July 21, 2025 at 2:15 PM
Reposted by Tiffany Goolsby, PharmD, BCIDP
The Complicated UTI Guidelines from IDSA are officially published.

www.idsociety.org/pr...

#IDSky
July 21, 2025 at 12:00 PM
Reposted by Tiffany Goolsby, PharmD, BCIDP
The latest issue of Prevention Strategist explains how the long-term care IP can decode the antibiogram. Check it out to see how you can protect vulnerable residents through antibiotic stewardship!

#NursingHome #InfectionPrevention

www.preventionstrate...
DECODING THE ANTIBIOGRAM: A Hidden Asset in Long-Term Care
It’s 10 p.m. in the long-term care...
www.preventionstrategist-digital.com
July 15, 2025 at 12:00 PM
Reposted by Tiffany Goolsby, PharmD, BCIDP
The recombinant zoster vaccine provides durable protection against shingles and post-herpetic neuralgia.

doi.org/10.1093/cid/...

PraediAlert can help you identify eligible patients who have not yet been vaccinated.

#vaccines #IDSky
Effectiveness of the Adjuvanted Recombinant Zoster Vaccine in Adults ≥50 Years in the United States
AbstractBackground. Recombinant zoster vaccine (RZV) was approved for adults aged ≥50 years in the United States to prevent herpes zoster (HZ) and postherp
doi.org
July 9, 2025 at 1:21 PM